Mark Day, Ph.D.

Professor of Urology and Translational Oncology


Dr. Day is a Professor of Urology and a member of the University of Michigan Comprehensive Cancer Center, the Program in Cellular and Molecular Biology and the Translational Oncology Program at the University of Michigan. Dr. Day received his Ph.D. in Molecular and Cellular Biology from Washington University School of Medicine in 1992 where he remained to join the faculty in the Department of Surgery. In 1995 he joined the University of Michigan to continue his research on the molecular and cellular basis of GU tumorigenesis. His current research focuses on the tumor microenvironment and the translation of discoveries into the development of new therapeutic approaches to treat GU cancers. Dr. Day has been the PI of numerous sponsored projects from the NIH, the Department of Defense, American Cancer Society and numerous private foundations. His leadership role in mentoring urology research trainees at all levels extends back to 1992 and includes the training of PhD students, medical students, post-doctoral fellows, Urology residents and international scholars. Dr. Day has also served advisory roles on multiple NIH, DOD, NSF, state and international scientific review panels.

Research Interests

Our research is focused on prostate and bladder epithelial adhesion and survival and the influence of the microenvironment on these processes and on tumorigenesis in these organs


Sun C, Wu MH, Guo M, Day M.L, Lee ES, Yuan SY, ADAM15 regulates endothelial permeability and neutrophil migration via Src/ERK/1/2 signaling. Cardiovasc Res. (87(2): 348-55 PMCID: 2895539. 

Grivas PD, Day M.L., Hussain M. Urothelial carcinomas: a focus on human  epidermal receptors signaling  Am J Transl Res. 2011;3(4):362-73. PMCID: 3158738.
Grivas PD, Day M.L.,Hussain M. Targeting cancer stem cell0like phenotype in bladder cancer (BC) cell lines. J Clin Oncol. 2011;29.

Grabowska, MM, Sandhu, B, Day M.L. EGF Promotes the Shedding of Soluble E-cadherin in an ADAM10-dependent manner in prostate epithelial cells. Cell Signal. 2012;24(2):532-8

Valdez, CV, Davis JN, Odeh HM, Layfield TL, Cousineay CS, Berton TR, Johnson DG, Wojno K,  Day M.L. Repression of Androgen Receptor Transcription through the E2F1/DNMT1 Axis.  PLoS One. 2011:6(9): e25187. PMCID: 3180375.

Grabowska, MM, Day M.L. Soluable E-cadherin: more than a symptom of disease. Front Biosci. 2012;17:1948-64.
Ithimakin S, Day KC, Malik F, Zen Q,Dawsey, et al. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification:  Implifications for efficacy of adjuvant trastuzumab. Cancer Res 73(5): 1635-1646. PMCID: 3600586.

Valdez CV, Kunju LP, Daugnault S, Wojno KJ, Day ML. The E2F1/DNMT1 Axis is Associated with the Development of AR Negative Castration Resistant Prostate Cancer.  Prostate. 2013 Dec;73(16):1776-85.

Grivas PD, Day KC, Karatsinides A,  Paul A, Shakir N, Owainati I, Liebert M, Kunju L, Thomas D,  Hussain M, Day ML. Evaluation of the Anti-Tumor Activity of Dacomitinib in Models of Human Bladder Cancer.  Mol Med. 2013 Nov 8;19:367-76. PMCID: 24166682

Hussain M, Daignault S, Agarwal N, Grivas PD,Siefker-Radtke AO, Puzanov I, Macvicar GR,  Levine EG, Srinivas S, Twardowski P,Eisenberger MA, Quinn DI, Vaishampayan UN, Yu EY, Dawsey S, Day KC, Day ML,et al. Cancer. 2014 May 6. PMCID:In process